✦ LIBER ✦

PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES' C COLON CANCER: PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL– DATA FROM CZECH PERSPECTIVE

✍ Scribed by L Jiraskova; T Dolezal

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

675 PUBLICATION Economic evaluation of c

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

634 POSTER Post-study treatment does not

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

1089 Improved safety of capecitabine vs

✍ Nowacki, M.; Kröning, H.; Cervantes, A.; Husseini, F.; McKendrick, J.; Schuller, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

1LB 5-year overall survival update from

✍ C. Twelves; W. Scheithauer; J. McKendrick; M. Nowacki; J. Seitz; G. Van Hazel; A 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 38 KB

617 POSTER Initial safety findings from

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB